Collegium Reports Third Quarter Fiscal 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Collegium Pharmaceutical (COLL) PT Lowered to $26 at Needham & Company
November 5, 2021 7:43 AM EDTNeedham & Company analyst Serge Belanger lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $26.00 (from $32.00) while maintaining a Buy rating.
The analyst commented, "Xtampza struggled in 3Q21 with sales of $30.0MM (-9%Q/Q and -7%Y/Y) due to... More
